Western blotting (0.5-4 μg/ml), detecting the pro- (~50 kDa) and the mature (~30 kDa) forms of Lox-1 in samples from human, mouse and rat origins. Other applications have not been determined.
This antibody is specific for LOX-1.
PBS (pH 7.2) containing 30% glycerol, 0.5% BSA, 0.01% thimerosal
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.5mg/ml(Please refer to the vial label for the specific concentration.)
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
OLR1, STK-10, Serine/Threonine Kinase10, Lymphocyte Oriented Kinase, STK10, LOK, Serine/Threonine Kinase 10, LOX1, STK 10
A secreted form also exists.
Lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1), also known as oxidized low-density-lipoprotein receptor-1 (OLR-1), belongs to the C-type lectin family. LOX-1 binds and supports the internalization of multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic or aged cells, and heat shock proteins. Human LOX-1 gene encodes a 273 amino acid residues (aa) protein with a short N-terminal intracellular domain, a transmembrane domain, an extracellular stalk/neck region followed a C-type lectin-like domain (CTLD). The expression of LOX-1 is induced by proinflammatory or proatherogenic stimuli, as well as by oxidized LDL itself and hemodynamic or oxidative stress. LOX-1-dependent oxidized LDL uptake also induces apoptosis by inducing the expression of the pro-apoptotic Bax and downregulation of the anti-apoptotic Bcl-2.